Endovascular systems for deployment at branched arteries include a main tubular graft body deployable within a main artery including a proximal end and an opposed distal end. The proximal and distal ends have a tubular graft wall therein between. A plurality of inflatable channels are disposed along the main tubular graft body, and at least one stent segment is disposed along the tubular graft wall of the main tubular graft body. The plurality of inflatable channels are configured to be inflatable with an inflation medium. The at least one stent segment is disposed between two or more adjacent inflatable channels of the plurality of inflatable channels.

Embodiments of the invention provide compositions including bio degradable polymers, medical implants fabricated from these compositions and methods of using such implants. Many embodiments provide medical implants comprising a first polymer backbone having a first rate of biodegradation and a second polymer backbone having a second rate of biodegradation faster than the first rate. In some embodiments, the second backbone is configured to be replaced by a natural tissue layer. The first backbone provides a scaffold for the implant while the second backbone degrades. This scaffold can enhance mechanical properties of the implant including various aspects of mechanical strength such as tensile, bending, hoop and yield strength; and elasticity. The scaffold also serves to maintain a minimum level of structural support of the implant during the period of degradation of the second backbone or for the entire life of the implant so that the implant does not mechanically fail.

A medical device includes a body defining an exterior surface, and a coating including a therapeutic agent-containing nanoparticle disposed on the exterior surface of the medical device. The nanoparticle may include a brush-arm star polymer. The therapeutic agent may be paclitaxel.

The present invention relates to a stent implant for treating glaucoma by means of intraocular fluid drainage from the anterior chamber, preferably in the suprachoroidal space. The stent implant according to the invention is designed to bring about a change in shape after being inserted into the eye, during which change the width and/or thickness or the flow cross-section is increased by more than 20%, preferably more than 200%, and particularly preferably by more than 400%, at at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can therefore be at least largely or completely closed. The proposed stent implant is provided in particular for intraocular fluid drainage into the suprachoroidal space. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. Said implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

The present invention relates to a stent implant for treating glaucoma by means of intraocular fluid drainage from the anterior chamber, preferably in the suprachoroidal space. The stent implant according to the invention is designed to bring about a change in shape after being inserted into the eye, during which change the width and/or thickness or the flow cross-section is increased by more than 20%, preferably more than 200%, and particularly preferably by more than 400%, at at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can therefore be at least largely or completely closed. The proposed stent implant is provided in particular for intraocular fluid drainage into the suprachoroidal space. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. Said implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

The devices and methods described herein include an implantable body lumen fluid flow modulator including an upstream flow accelerator separated by a gap from a downstream flow decelerator. The gap is a pathway to entrain additional fluid from a branch lumen(s) into the fluid stream flowing from the upstream flow accelerator to the downstream flow decelerator.

The devices and methods described herein include an implantable body lumen fluid flow modulator including an upstream flow accelerator separated by a gap from a downstream flow decelerator. The gap is a pathway to entrain additional fluid from a branch lumen(s) into the fluid stream flowing from the upstream flow accelerator to the downstream flow decelerator.

According to one aspect, a medical system may include an instrument including an end effector for acting as a monopolar electrode. The end effector may be configured to be positioned in a body of a subject and emit radiofrequency energy towards a target area in the body. The medical system may further include a return electrode. The return electrode may be deliverable within the body proximate the target area and separately from the instrument and the monopolar electrode. The return electrode may be configured to contact tissue in the body proximate the target area and receive radiofrequency energy emitted from the end effector.

According to one aspect, a medical system may include an instrument including an end effector for acting as a monopolar electrode. The end effector may be configured to be positioned in a body of a subject and emit radiofrequency energy towards a target area in the body. The medical system may further include a return electrode. The return electrode may be deliverable within the body proximate the target area and separately from the instrument and the monopolar electrode. The return electrode may be configured to contact tissue in the body proximate the target area and receive radiofrequency energy emitted from the end effector.

A thermoplastic vascular structure has a first thermoplastic sheet including at least one first recess; and a second thermoplastic sheet. The first thermoplastic sheet is attached to the second thermoplastic sheet to create a continuous branched vascular network structure. The at least one first recess creates at least one fluid channel through the continuous branched vascular network structure. The second thermoplastic sheet may have at least one second recess. The at least one first recess of the first thermoplastic sheet may align with the at least one second recess of the second thermoplastic sheet to create the at least one fluid channel through the continuous branched vascular network structure.